The tests run on the firm's sample-to-result automated molecular diagnostics instruments designed for use by high-volume labs.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.
An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.